drugset
drugset / Trial / NCT06832982

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

NCT06832982 ↗

Phase 1 Recruiting 66 enrolled Shanghai Pushi Medical Science Co. Ltd
NaSequentialOpen-labelTreatment

Summary

this is a single-arm, open phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics, and preliminary efficacy of FS-8002 and combination therapy in patients with advanced solid tumors

Timeline

Start
2025-02-24
Primary completion
2028-02-19
Completion
2028-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject FS-8002 Unknown — —
Subject Toripalimab Monoclonal antibody — —

Indications

cancer